L15 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:360773 CAPLUS Full-text
DN 147:9874
TI Parallel Synthesis of a Novel C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Library
AU Antonow, Dyeison; Cooper, Nectaroula; Howard, Philip W.; Thurston, David E.
CS Spirogen Limited, London, NW1 0NH, UK
SO Journal of Combinatorial Chemistry (2007), 9(3), 437-445
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 147:9874
GI



I

AB A 66-membered library of C2-aryl pyrrolo[2,1-c][1,4]benzodiazepines I [R = Ph, 4-MeOC6H4, 3-H2NC6H4, 2-F3CC6H4, 4-(4-methyl-1-piperazinyl)phenyl, 2-thienyl, 4-pyridyl, 2-naphthyl, etc.] has been successfully prepared by parallel synthesis via Suzuki coupling using polystyrene-bound Pd(PPh3)4 as catalyst and polystyrene-bound diethanolamine as scavenger under microwave irradiation Library members were obtained in sufficient yields (up to 91%) and purity (85-98% crude) for biol. evaluation.

IT 864754-74-5P 937720-37-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(parallel synthesis of aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine library via Suzuki coupling under microwave irradiation)

RN 864754-74-5 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7,8-dimethoxy-5-oxo-2-[[(trifluoromethyl)sulfonyl]oxy]-, 2,2,2-trichloroethyl ester, (11S,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 937720-37-1 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7,8-dimethoxy-2-(4-methoxyphenyl)-5-oxo-, 2,2,2-trichloroethyl ester, (11S,11aS)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1124678 CAPLUS Full-text
DN 145:455035
TI Preparation of pyrrolobenzodiazepine derivatives for treatment of proliferative diseases
IN Gregson, Stephen John; Howard, Philip Wilson; Chen, Zhizhi
PA Spirogen Limited, UK
SO PCT Int. Appl., 77pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2006111759 | A1 | 20061026 | WO 2006-GB1456 | 20060421 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | AU 2006238686 | A1 | 20061026 | AU 2006-238686 | 20060421 |
| | CA 2604805 | A1 | 20061026 | CA 2006-2604805 | 20060421 |
| | GB 2439881 | A | 20080109 | GB 2007-20721 | 20060421 |
| | EP 1879901 | A1 | 20080123 | EP 2006-726846 | 20060421 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | JP 2008536905 | T | 20080911 | JP 2008-507165 | 20060421 |
| | IN 2007DN07862 | A | 20071109 | IN 2007-DN7862 | 20071011 |
| | US 20080167293 | A1 | 20080710 | US 2007-911890 | 20071018 |
| | MX 2007013039 | A | 20080313 | MX 2007-13039 | 20071019 |
| | CN 101171257 | A | 20080430 | CN 2006-80015716 | 20071108 |
| | KR 2008004618 | A | 20080109 | KR 2007-727047 | 20071120 |
| PRAI | GB 2005-8084 | A | 20050421 | | |
| | GB 2005-22746 | A | 20051107 | | |
| | WO 2006-GB1456 | W | 20060421 | | |

OS CASREACT 145:455035; MARPAT 145:455035
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. with general formula I [wherein: R2 = (un)substituted aryl; R6 and R9 = independently H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn, or halo, where R and R' = independently (un)substituted alkyl, heterocyclyl, or aryl; R7 = H, R, OH, OR, SH, SR, NH2, NHR, NHRR', nitro, Me3Sn, or halo; Z = alkylene; X = O, S, or NH; n = 2 or 3] or pharmaceutically acceptable salts or solvates thereof are prepared for the treatment of proliferative diseases. For example, compound II•2Na was prepared in a multi-step synthesis. II•2Na showed IC50 of 1.5 nM in the In Vitro cytotoxicity test with K562 human chronic myeloid leukemia cells.

IT 864754-61-8P 864754-66-5P 913262-19-8P
913262-21-2P 913262-23-4P 913262-24-5P
913262-26-7P 913262-28-9P 913262-38-1P

913262-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of pyrrolobenzodiazepine derivs. for treatment of proliferative diseases)

RN 864754-61-0 CAPLUS

CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-[[(trifluoromethyl)sulfonyl]oxy]-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



RN 864754-66-5 CAPLUS

CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-2-(4-methoxyphenyl)-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-19-8 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-2-(2-naphthalenyl)-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-21-2 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-(2-

thienyl)-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 913262-23-4 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-(7-quinolinyl)-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-24-5 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-2-(3-methoxyphenyl)-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-26-7 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[2-(1,3-benzodioxol-5-yl)-11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 913262-28-9 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-(4-fluorophenyl)-11,11a-dihydro-7-methoxy-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-38-1 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,5-pentanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-[[(trifluoromethyl)sulfonyl]oxy]-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 913262-39-2 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,5-pentanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-2-(4-methoxyphenyl)-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1004748 CAPLUS Full-text
DN 143:306348
TI Preparation of pyrrolobenzodiazepinone derivatives as antitumor agents
IN Howard, Philip Wilson; Gregson, Stephen John
PA Spirogen Limited, UK
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005085251 | A1 | 20050915 | WO 2005-GB768 | 20050301 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005219626 | A1 | 20050915 | AU 2005-219626 | 20050301 |
| | CA 2558195 | A1 | 20050915 | CA 2005-2558195 | 20050301 |
| | EP 1720881 | A1 | 20061115 | EP 2005-717846 | 20050301 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| | JP 2007525535 | T | 20070906 | JP 2007-501340 | 20050301 |
| | US 20070173497 | A1 | 20070726 | US 2007-598518 | 20070206 |
| PRAI | GB 2004-4575 | A | 20040301 | | |
| | GB 2004-26392 | A | 20041201 | | |
| | WO 2005-GB768 | W | 20050301 | | |

OS CASREACT 143:306348; MARPAT 143:306348
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = labile leaving group, alkenyl or substituted phenyl; R2 and R5 independently = H, OH, SH, etc.; R3 and R4 independently = H, NH2, halo, etc. or the compound is a dimer with each monomer being of formula I, where the R3 and R4 groups of each monomer form together a dimer bridge -X-R-X-; R = alkylene group, which may be interrupted by heteroatoms or aromatic rings; X = O, S or NH; R6 = carbamate-based N-protecting group; R7 = oxygen protecting group or OH or R6 and R7 together form double bond between N10 and C11] and their pharmaceutically acceptable salts, are prepared and disclosed as antitumor agents. Thus, e.g., II was prepared by palladium catalyzed coupling of III (preparation given) with trans-propenylboronic acid followed by deprotection. The in vitro cytotoxicity of I towards K562 human chronic myeloid leukemia cells was evaluated using ELISA assay and it was revealed that selected compds. of the invention displayed IC50 values of less than 1 μM. I should prove useful in the treatment of proliferative diseases such as leukemia. Pharmaceutical comprns. comprising I are disclosed.

IT 864754-61-6P 864754-63-2P 864754-66-5P
864754-70-1P 864754-72-3P 864754-74-5P
864754-75-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrrolobenzodiazepinone derivs. as antitumor agents)

RN 864754-61-0 CAPLUS

CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-[[(trifluoromethyl)sulfonyl]oxy]-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A




PAGE 1-B




RN 864754-63-2 CAPLUS

CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[2-[(1E)-3-(dimethylamino)-3-oxo-1-propenyl]-11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 864754-66-5 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-2-(4-methoxyphenyl)-5-oxo-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 864754-70-1 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-(1E)-1-propenyl-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 864754-72-3 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8,8'-[1,3-propanediylbis(oxy)]bis[11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7-methoxy-5-oxo-2-(phenylethynyl)-, bis(2,2,2-trichloroethyl) ester, (11S,11'S,11aS,11'aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 864754-74-5 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7,8-dimethoxy-5-oxo-2-[[(trifluoromethyl)sulfonyl]oxy]-, 2,2,2-trichloroethyl ester, (11S,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 864754-75-6 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 11-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-11,11a-dihydro-7,8-dimethoxy-5-oxo-2-(1E)-1-propen-1-yl-, 2,2,2-trichloroethyl ester, (11S,11aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:139855 CAPLUS Full-text
DN 94:139855
OREF 94:22905a,22908a
TI Benzodiazepines
PA Green Cross Corp., Japan
SO Belg., 24 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | BE 882305 | A1 | 19800716 | BE 1980-199851 | 19800319 |
| | JP 56015289 | A | 19810214 | JP 1979-89886 | 19790717 |
| | JP 62037631 | B | 19870813 | | |
| | SE 8001458 | A | 19810118 | SE 1980-1458 | 19800225 |
| | SE 436882 | B | 19850128 | | |
| | SE 436882 | C | 19850509 | | |
| | CA 1152985 | A1 | 19830830 | CA 1980-346511 | 19800227 |
| | US 4309437 | A | 19820105 | US 1980-127984 | 19800304 |
| | GB 2053894 | A | 19810211 | GB 1980-8033 | 19800310 |
| | GB 2053894 | B | 19830420 | | |
| | NL 8001531 | A | 19810120 | NL 1980-1531 | 19800314 |
| | DE 3010544 | A1 | 19810129 | DE 1980-3010544 | 19800319 |
| | DE 3010544 | C2 | 19820701 | | |
| | FR 2461711 | A1 | 19810206 | FR 1980-6153 | 19800319 |
| | FR 2461711 | B1 | 19830513 | | |
| | CH 648848 | A5 | 19850415 | CH 1980-2187 | 19800320 |
| PRAI | JP 1979-89886 | A | 19790717 | | |

OS MARPAT 94:139855
GI

http://www.uspto.gov




I

AB Pyrrolobenzodiazepines I (R = H, acyl, CONH2, alkoxycarbonyl; R1 = H, acyl; R2 = SO2H) were prepared by treating I (R2 = OMe) with Na dithionite. I (R2 = SO3H) were prepared by oxidizing I (R2 = SO2H) or by treating I (R2 = OMe) with SO2 or K2SO3. Thus, 1 g I (R = R1 = Ac, R2 = OMe) was treated with Na dithionite to give 0.8 g I (R = R1 = Ac, R2 = SO2H), which at 0.12 mg/kg daily i.p. for 6 days increased the survival time of leukemia P388 infected mice by 190%.

IT 77004-92-3 77004-94-5 77004-97-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfination of)

RN 77004-92-3 CAPLUS

CN 2-Propenamide, 3-(10-acetyl-5,10,11,11a-tetrahydro-9-hydroxy-11-methoxy-8-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl)- (CA INDEX NAME)



RN 77004-94-5 CAPLUS
CN 2-Propenamide, 3-[10-acetyl-9-(acetyloxy)-5,10,11,11a-tetrahydro-11-methoxy-8-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl]- (CA INDEX NAME)



RN 77004-97-8 CAPLUS
CN 2-Propenamide, 3-[10-acetyl-9-[(aminocarbonyl)oxy]-5,10,11,11a-tetrahydro-11-methoxy-8-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl]- (CA INDEX NAME)



L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1970:531049 CAPLUS Full-text
DN 73:131049
OREF 73:21357a,21360a
TI Antiprotozoal, anthelmintic, and antitumor benzodiazepine compounds
IN Leimgruber, Willy; Schenker, Fausto E.
PA Hoffmann-La Roche Inc.
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 3523941 | A | 19700811 | US 1967-620618 | 19670306 |
| PRAI US 1967-620618 | A | 19670306 | | |

GI For diagram(s), see printed CA Issue.

AB The acetates of I and II were prepared by acylation of the corresponding 9-OH derivative I (R1 = R2 = H, R3 = α-OMe) (III), or its hydrate. The epimers of I were prepared by acylating III, removing the elements of MeOH from the mol. by an 8 hr reflux with H2C:C(Me)OAc and treating the product with MeOH at room temperature Thus, III in 1:1 Ac2O-NEt3 stirred 4 hr at 20° gave (11R,11aS)-5,10,11,11a-tetrahydro-9-hydroxy-11-methoxy-8- methyl-5-oxo- 1H-pyrrolo[2,1-c][1,4]benzodiazepine-2-trans-acrylamide acetate (IV). (11S,11aS)-Epimer of IV was similarly prepared and had the same activity against S 180 and Ehrlich solid tumors in mice. II (R1 = H) stirred 2 hr at 20° in 1:1 Ac2O-C5H5N gave II (R1 = Ac) (V). V in 4:1 H2O-Me2CO kept 18 hr at 20° gave I (R1 = H, R2 = Ac, R3 = OH) (VI). V in C5H5N kept 3 days at 20° in AcOH-Ac2O gave I (R1 = R2 = Ac, R3 = AcO). Treatment of III.H2O with (EtCO)2O-NEt3, (PrCO)2O-NEt2, or Bz3O-NEt3 gave I (R1 = EtCO, PrCO, or Bz). Similar acylations of III.H2O with PhNCO, EtNCO, or (EtO)2CO in the presence of NEt3 gave I (R1 = PhNHCO, EtNHCO, EtCO2). I are useful as antitumor agents against Sarcoma 180 and Ehrlich solid tumors in mice, as antiprotozoal agents against Entamoeba histolytica and Trichomonas vaginalis, and as anthelmintic agents against Syphacia obvelata.

IT 29455-46-7P 29455-48-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29455-46-7 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-2-acrylamide, 10-acetyl-5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-, diacetate (ester), (E)-(S,S)-(+)- (8CI) (CA INDEX NAME)



RN 29455-48-9 CAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-2-acrylamide, 5,10,11,11a-tetrahydro-9-hydroxy-11-methoxy-8-methyl-5-oxo-10-propionyl-, propionate (ester), (E)-(11R,11aS)- (8CI) (CA INDEX NAME)


O
Et—C—O
Me
Et—C
O
N
OMe
CH═CH—C
O
NH2
N
O

```
=> d l2; d l6; d l11; d his; log y
L2 HAS NO ANSWERS
L1              STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L2              QUE  ABB=ON  PLU=ON  L1

L6 HAS NO ANSWERS
L5              STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L6              QUE  ABB=ON  PLU=ON  L5

L11 HAS NO ANSWERS
L10             STR
```



```
Structure attributes must be viewed using STN Express query preparation.
L11             QUE  ABB=ON  PLU=ON  L10

     (FILE 'HOME' ENTERED AT 10:40:14 ON 11 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 10:41:15 ON 11 MAR 2009
L1              STRUCTURE UPLOADED
L2              QUE L1
L3            8 S L2
L4          215 S L2 FUL
L5              STRUCTURE UPLOADED
L6              QUE L5
L7            5 S L6 SAM SUB=L4
L8          145 S L6 FUL SUB=L4
L9           70 S L4 NOT L8
L10             STRUCTURE UPLOADED
L11             QUE L10
L12           2 S L11 SAM SUB=L9
L13          49 S L11 FUL SUB=L9
L14          21 S L9 NOT L13

     FILE 'CAPLUS' ENTERED AT 10:45:45 ON 11 MAR 2009
L15           5 S L14
```

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 29.20 | 306.88 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -4.10 | -4.10 |

STN INTERNATIONAL LOGOFF AT 10:46:51 ON 11 MAR 2009